Inclisiran fails to find place in AACE 2025 Dyslipidemia Guidelines Nidhi Srivastava22 Feb 2025 8:45 AM ISTOhio: Once pegged as a blockbuster medicine for lowering LDL, long-acting small interfering RNA, Inclisiran failed to find any place in the...
Inclisiran be sold by retail under prescription of cardiologist only: CDSCO panel tells Novartis Healthcare Dr. Divya Colin7 Dec 2024 5:30 PM ISTNew Delhi: Rejecting the drug major Novartis Healthcare's proposal for amendment in the warning statement of Inclisiran Solution for injection, the...
Inclisiran Lowers LDL Cholesterol Across Glycaemic and BMI Strata, suggests study Dr Riya Dave17 Aug 2024 9:30 AM ISTResearchers have found that inclisiran significantly lowers LDL cholesterol across various glycaemic and BMI strata, with consistent efficacy and...
CDSCO panel Approves Novartis Protocol Amendment proposal to study inclisiran Dr. Divya Colin4 Aug 2024 5:00 PM ISTNew Delhi: The Subject Expert Committee SEC functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major...
CDSCO Panel Grants Novartis Protocol Amendment Proposal For anti-cholesterol drug Inclisiran Dr. Divya Colin28 Jan 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Extended use of inclisiran safe and efficacious among refractory dyslipidemia in patients with increased CV risk Dr Riya Dave29 Dec 2023 8:45 PM ISTA recent study sheds light on the safety profile of inclisiran, an innovative agent designed to reduce low-density lipoprotein cholesterol (LDL-C)....
Novartis gets CDSCO Panel Nod To Import, Market Inclisiran solution for injection Dr. Divya Colin15 July 2023 6:00 PM ISTNew Delhi: After deliberating the interim data of a Phase-III global clinical trial of Inclisiran solution for injection presented by pharmaceutical...
FDA approves expanded use of inclisiran for primary hyperlipidemia Dr. Kamal Kant Kohli13 July 2023 10:00 AM ISTThe US Food and Drug Administration has approved expanded use of inclisiran (Leqvio) for primary hyperlipidemia besides its existing indications of...
Inclisiran treatment in high-risk patients provides sustained reductions in LDL-cholesterol: ORION-3 Medha Baranwal19 Jan 2023 9:30 AM ISTUSA: In patients with high cardiovascular risk and elevated LDL cholesterol, twice-yearly inclisiran provided early reductions in LDL cholesterol and...
Inclisiran safely reduces LDL-C in primary prevention patients with elevated levels: Study Medha Baranwal19 Nov 2022 11:45 AM ISTTwice-yearly maintenance dosing with inclisiran significantly reduces LDL-C and other atherogenic lipoprotein measurements in patients without...
Orion – 4 trial: Inclisiran effective in reducing cholesterol Dr. Nandita Mohan12 Feb 2022 11:04 AM ISTInclisiran is a popular drug, studied for its effect to control bad cholesterol or LDL levels in blood, a proprotein convertase subtilisin/kexin type...
Inclisiran effective in controlling LDL Cholesterol: ORION-4 Trial MD Editorial Team5 Feb 2022 9:00 AM ISTInclisiran is a drug that reduces the amount of LDL-C in the bloodstream by improving the liver's natural ability to prevent the production of a...
